Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (5086)	8/6/1998 12:05:00 PM
From: Pseudo Biologist	Read Replies (1) of 6136

Re: Chiron's claims: One can get the patent numbers from the press release: biz.yahoo.com Then plug them into the IBM patent site: patents.ibm.com patents.ibm.com patents.ibm.com Without getting into much detail, it seems to me Chiron cloned the HCV protease and developed some assays to test for inhibitors. The latter's claims are broad enough, in Chiron's mind at least, as to believe that anyone developing HCV protease inhibitors should get a license. Regardless of the merits of Chiron's claims, I see a possible trend here in which cloners and genomics workers can try to claim not just direct use of the proteins (for which the new genes code), but also other uses important for small molecule drug discovery. Coverage for more "obvious" uses such as antibodies to, or antisense that block expression of, the proteins have been routinely allowed as claims for quite some time (just read any recent patent by HGS or Millennium, for example). PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next